Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis

Journal of Dermatology

Volumn 39, Issue 6, 2012, Pages 536-540

  Yoshimasu, Takashi ^a,b   Ikeda, Takaharu ^b   Uede, Koji ^c   Kanazawa, Nobuo ^b   Furukawa, Fukumi ^b  

^a Arida Municipal Hospital   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c WAKAYAMA ROSAI HOSPITAL   (Japan)

Author keywords

collagen disease; Raynaud's phenomenon; sarpogrelate; skin ulcer; systemic sclerosis

Indexed keywords

SARPOGRELATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; DRUG EFFECT; EMOTION; FEMALE; HUMAN; MALE; QUALITY OF LIFE; SKIN ULCER; SKINDEX 16; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SKIN ULCER; SUCCINATES;

EID: 84861096724     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01432.x     Document Type: Article

References (14)

1. Fitzpatrick TB, Bernhard JD, Cropley TG,. The Structure of Skin Lesions and Fundamentals of Diagnosis. Fitzpatrick's Dermatology in General Medicine, 5th edn. New York, McGraw-Hill, 1999; 28-29.
2. 2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004; 104: 59-81. (Pubitemid 39410563)
3. 2c receptor subtypes by molecular modeling. Life Sci 2003; 73: 193-207. (Pubitemid 36555937)
4. 2-serotonergic receptor antagonist. Thromb Haemost 1991; 65: 415-420.
5. Hara H, Osakabe M, Yamada Y, et al. Effect of sarpogrelate hydrochloride on contraction of blood vessel. Jpn Pharmacol Ther 1991; 19: S611-S618 (in Japanese).
6. Hara H, Kitajima A, Tamao Y,. Improvement of red blood cell deformability by a new anti-platelet agent, MCI-9042. Clin Hemorheol 1992; 12: 267-277.
7. Biondi ML, Marasini B, Bianchi E, et al. Plasma free and intra platelet serotonin in patients with Raynaud's phenomenon. Int J Cardiol 1988; 19: 335-339.
8. 2 receptor antagonist. J Dermatol 2000; 27: 643-650.
9. Kumagai S, Morinobu A, Ozaki S, et al. Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen disease. Ryumachi 1998; 38: 504-510 (in Japanese). (Pubitemid 28354242)
10. Kato S, Izumi K, Ohnuma N, et al. Suppressive effect of sarpogrelate hydrochloride on Raynaud's phenomenon and respiratory failure in patients with systemic sclerosis. Respirology 2000; 5: 27-32. (Pubitemid 30163440)
11. Higaki Y, Kawamoto K, Kamo T, et al. The Japanese version of skindex-16: a brief quality-of-life measure for patients with skin diseases. J Dermatol 2002; 29: 693-698. (Pubitemid 35416255)
12. Friedhoff LT, Seibold JR, Kim HC, et al. Serotonin induced platelet aggregation in systemic sclerosis. Clin Exp Rheumatol 1984; 2: 119-123. (Pubitemid 14055557)
13. Coffman JD, Clement DL, Creager MA, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989; 87: 264-268. (Pubitemid 19234277)
14. Miyazaki M, Higashi Y, Goto C, et al. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol 2007; 49: 221-227. (Pubitemid 46626014)